Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 17, 2017

Mel-Mont Medical develops self-collected diagnostic test for cervical cancer

Mel-Mont Medical has developed a new preventive comprehensive diagnostic system for cervical cancer called Mía by XytoTest.

Mel-Mont Medical has developed a new preventive comprehensive diagnostic system for cervical cancer called Mía by XytoTest.

The new system comes with a medical device that enables self-collection of cervical cells in any setting without assistance.

The collected sample is later analysed to identify human papillomavirus (HPV) using a molecular system of real-time polymerase chain reaction (PCR).

The same cells can also be used for a progressive protein analysis to identify the potential risk of high-grade lesions (CIN 2+) or cervical cancer in samples of high-risk HPV positive.

Mel-Mont Medical chief operating officer Frank Meléndez said: "The idea for Mía by XytoTest arose from the need to raise awareness on the importance of the culture of self-care and prevention to fight diseases with high morbidity and mortality rates that are paradoxically preventable, such as cervical cancer.”

"The idea for Mía by XytoTest arose from the need to raise awareness on the importance of the culture of self-care and prevention to fight diseases with high morbidity and mortality rates."

The test is based on the discovery by German doctor Harald Zur Hausen that HPV causes cervical cancer.

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

Mel-Mont Medical chief executive officer Liliana Montes said: "We created Mía by XytoTest to reduce sociocultural barriers that prevent the participation of women in the organised screening programmes of cervical cancer, giving them the possibility of obtaining their sample from the comfort of their home or in the doctor's office without the need for professional assistance.”

The comprehensive system is expected to improve gynaecological intervention, prevent unnecessary deaths and provide better population coverage to prevent cervical cancer.

As compared to the Pap smear test with 30%-50% sensitivity, the new preventive diagnostic system is claimed to hold 96% sensitivity in the results.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU